Taacr News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Taacr. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Taacr Today - Breaking & Trending Today

Toxicities Hinder Potential Efficacy of Ceritinib/Trametinib in Pretreated Advanced Melanoma

Zeynep Eroglu, MD, discusses how findings from a phase 1/2 study of ceritinib and trametinib could help inform future research in melanoma. ....

Zeynep Eroglu , Keiran Smalley , Moffitt Cancer Center , Department Of Oncologic Sciences , Cutaneous Oncology , Oncologic Sciences , South Florida Morsani College , Ceritinib And Trametinib ,

Tivumecirnon Plus Pembrolizumab Shows Activity in Checkpoint Inhibitor–Exposed Recurrent/Metastatic HNSCC

Tivumecirnon plus pembrolizumab elicited responses in recurrent or metastatic head and neck squamous cell carcinoma after checkpoint inhibitor exposure. ....

North Carolina , United States , Duke University , Jameel Muzaffar , Duke Cancer Institute In Durham , Duke University School Of Medicine , Department Of Medicine , Duke University School , Duke Cancer Institute , Head And Neck Squamous Cell Carcinoma ,

Proteogenomic Signatures Shed Light on Prostate Cancer Recurrence Risk in Select Ancestries

A proteomics analysis revealed significant variations in protein expression and informative markers between African vs European prostate tumors. ....

United States , South Korea , Cara Schafer , Prostate Disease Research , Department Of Surgery , Uniformed Services University Of The Health Sciences , Henrym Jackson Foundation , Research Network , Johnp Murtha Cancer Center , Walter Reed National Military Medical Center , Uniformed Services University , Health Sciences , Applied Proteogenomic Organizational Learning , Cancer Center , Walter Reed National Military Medical , Shyh Han Tan , Proteogenomic Signatures , Prostate Cancer , Recurrence Risk , Aacr Annual Meeting ,

Mirvetuximab Soravtansine Plus Pembrolizumab Makes a Splash in pMMR/MSS FRalpha+ Endometrial Cancer

Mirvetuximab soravtansine plus pembrolizumab in patients with recurrent or persistent, FRalpha-positive, pMMR/MSS serous endometrial cancer, according to findings from a phase 2 trial. ....

United States , Rebeccal Porter , Gynecologic Oncology Program , Dana Farber Cancer Institute , Dana Farber Cancer Institute , Pmmr Mss Serous Endometrial Cancer , Phase 2 Trial Nct03835819 , Mirvetuximab Soravtansine Elahere And Pembrolizumab Keytruda ,

AZD1390 Demonstrates Initial Safety, May Enhance Radiotherapy Efficacy in Glioblastoma

Early safety and efficacy data seen with AZD1390 in a phase 1 study indicate it's potential utility as a radiosensitizing treatment in glioblastoma. ....

Jonathant Yang , Memorial Sloan Kettering Cancer Center , Azd1390 ,